Fig. 1 · Structure
Documents & Downloads
Indusatumab vedotin
ADC
Indusatumab vedotin is an antibody-drug conjugate (ADC) targeting guanylate cyclase C (GCC). Its mechanism involves the delivery of the microtubule-disruptor Monomethyl auristatin, leading to anti-proliferative effects in pancreatic cancer cell lines. Indusatumab vedotin effectively induces cell cycle arrest at the G2/M phase and promotes apoptosis, making it a valuable reagent for cancer research and therapeutic development.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1514889-12-3 |
| Applications | ADC |
| Synonyms | MLN0264; TAK-264 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.